Established in 2017 and based in Allschwil, Switzerland, Idorsia Ltd operates as a biopharmaceutical company focused on discovering, developing, and commercializing innovative medicines to address significant unmet medical needs. The company's diverse clinical development pipeline targets various therapeutic areas, including central nervous system (CNS), cardiovascular, and immunological disorders, alongside treatments for rare (orphan) diseases. Idorsia maintains a portfolio of strategic alliances: a joint development and commercialization agreement with Janssen Biotech Inc. for aprocitentan and its related products; a licensing deal with Mochida Pharmaceutical for the supply, co-development, and co-marketing of daridorexant; and a collaboration with Hoffman-La Roche Inc. to advance and market cancer immunotherapy compounds. Additionally, Idorsia is partnering with Antares Pharma, Inc. to create a self-administered drug device product for Selatogrel, and with Neurocrine Biosciences, Inc. to develop and commercialize ACT-709478, which is currently undergoing Phase II clinical trials for epilepsy.
—
Established in 2017 and based in Allschwil, Switzerland, Idorsia Ltd operates as a biopharmaceutical company focused on discovering, developing, and commercializing innovative medicines to address significant unmet medical needs. The company's diverse clinical development pipeline targets various therapeutic areas, including central nervous system (CNS), cardiovascular, and immunological disorders, alongside treatments for rare (orphan) diseases. Idorsia maintains a portfolio of strategic alliances: a joint development and commercialization agreement with Janssen Biotech Inc. for aprocitentan and its related products; a licensing deal with Mochida Pharmaceutical for the supply, co-development, and co-marketing of daridorexant; and a collaboration with Hoffman-La Roche Inc. to advance and market cancer immunotherapy compounds. Additionally, Idorsia is partnering with Antares Pharma, Inc. to create a self-administered drug device product for Selatogrel, and with Neurocrine Biosciences, Inc. to develop and commercialize ACT-709478, which is currently undergoing Phase II clinical trials for epilepsy.
—
Daily adjusted close
Established in 2017 and based in Allschwil, Switzerland, Idorsia Ltd operates as a biopharmaceutical company focused on discovering, developing, and commercializing innovative medicines to address significant unmet medical needs. The company's diverse clinical development pipeline targets various therapeutic areas, including central nervous system (CNS), cardiovascular, and immunological disorders, alongside treatments for rare (orphan) diseases. Idorsia maintains a portfolio of strategic alliances: a joint development and commercialization agreement with Janssen Biotech Inc. for aprocitentan and its related products; a licensing deal with Mochida Pharmaceutical for the supply, co-development, and co-marketing of daridorexant; and a collaboration with Hoffman-La Roche Inc. to advance and market cancer immunotherapy compounds. Additionally, Idorsia is partnering with Antares Pharma, Inc. to create a self-administered drug device product for Selatogrel, and with Neurocrine Biosciences, Inc. to develop and commercialize ACT-709478, which is currently undergoing Phase II clinical trials for epilepsy.